- Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors September 2021
Inflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant August 2021- Kamuvudines May be Answer to Preventing Blindness in Aging Population April 2021
- Inflammasome Therapeutics Says Study Published Today in Proceedings of the National Academy of Sciences Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMD February - 2021
- Inflammasome Therapeutics Says Study Approximately 130,000 People Reported in Nature Communications Points to Potential for Treatment or Prevention of Diabetes and Other Inflammasome-Mediated Diseases with Company's Drugs September - 2020
- Inflammasome Therapeutics Receives Grant to Develop Sustained Release Bioerodible Birth Control Implant from The Gates Foundation September - 2020
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases September - 2019